What share of U.S. paid biologic prescriptions did Tezspire capture?
Statista reports that Tezspire (tezepelumab) accounted for 7.1 % of all paid biologic prescriptions in the United States between May 2023 and April 2024.
How does that compare to other biologics for asthma?
Tezspire’s 7.1 % slice places it among the top performers for biologic asthma treatments, but it remains behind high‑volume options such as omalizumab and mepolizumab, which together command roughly 30 % of the market share in the same period.
When did Tezspire reach this level of penetration?
The 7.1 % figure represents the latest full year of data available from Statista. Prior to May 2023, the drug’s share hovered around 4–5 %, showing a steady climb since its U.S. launch in 2022.
Who publishes these numbers and how reliable are they?
Statista aggregates prescription data from multiple industry trackers and pharmacy claims databases. The figures are considered industry standard for market‑share analyses, though they are estimates rather than absolute counts.
What does a 7.1 % share mean for patients, payers, and clinicians?
For patients, a higher share suggests wider availability and potentially greater familiarity among prescribers. For payers, it signals significant utilization, which can influence formulary decisions and reimbursement negotiations. Clinicians may view it as a benchmark when considering treatment options relative to cost, efficacy, and patient adherence.
What trends could shift Tezspire’s market share in the next year?
Key drivers include new competitor approvals (e.g., dupilumab extensions), real‑world efficacy data, insurance coverage expansions, and pricing strategies. Any of these could either accelerate growth or erode the current 7.1 % position.
Are there any risks or uncertainties surrounding this data?
The primary uncertainty lies in the accuracy of claim attribution, especially for off‑label use or patient self‑insurance. Additionally, upcoming patent or exclusivity expirations for rival biologics could alter competitive dynamics.
How might Tezspire’s market share impact its pricing strategy?
Higher utilization often strengthens a company’s negotiating position with insurers, potentially allowing for premium pricing. Conversely, increased competition may pressure prices downward if payers seek cost‑effective alternatives.
Where can I find the raw data for deeper analysis?
Statista’s detailed reports, accessible through subscription, provide month‑by‑month prescription counts, payer mix, and demographic breakdowns for Tezspire and competing biologics.
[1] Statista – Tezspire Market Share, U.S. Paid Biologic Prescriptions, May 2023‑April 2024.